The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy.
In this educational activity, expert faculty review a clinical case series highlighting the application of CDK4/6 inhibitors in HR+/HER2− eBC, including identification of patients at high risk of recurrence/progression, selection of adjuvant therapy based on the latest clinical evidence and patient-specific factors, and management of treatment-related adverse events. Approaches to recognizing and addressing racial/ethnic health disparities among minority patients will also be discussed, empowering clinicians to make informed decisions that align with achieving health equity.
=Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Accurate Staging and Determining Resectability in NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video